Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
Sandra Kurtin, RN, MS, AOCN®, ANP-C, Carol S. Knop, RN, MS, AOCN®, and Todd Milliron, RN, SCN I
From University of Arizona Cancer Center, Tucson, Arizona; Northwestern Medical Faculty Foundation, Chicago, Illinois; and University of Maryland Medical System, Baltimore, Maryland
Sandra Kurtin has acted as a consultant and served on speakers bureaus for Celgene, Millennium Pharmaceuticals, and Onyx Pharmaceuticals. Carol S. Knop has served on an advisory board for Millennium Pharmaceuticals.
Correspondence to: Sandra Kurtin, RN, MS, AOCN®, ANP-C, University of Arizona Cancer Center, 6950 North Chaparral Place, Tucson, AZ 85718. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2012;3:406–410 |
DOI: 10.6004/jadpro.2012.3.6.8 |
© 2012 Harborside Press®
Bortezomib (Velcade) is approved by the FDA for IV or SC injection in select patients with multiple myeloma or mantle cell lymphoma. The SC route functions as an alternative to IV administration for patients with poor IV access. Learn about effective strategies used to reduce injection site reactions that can occur with SC delivery.
For access to the full length article, please sign in